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Soluble c-erbB-2 fragment in serum correlates with disease stage and
predicts for shortened survival in patients with early-stage and advanced
breast cancer
H. Kandl, L. Seymour & W.R. Bezwoda
Division ofClinical Haematologv and Medical Oncology, Department ofMedicine, Univ ersitY ofthe Witwatersrand,
Johannesburg, South Africa.
Suinmary Seventy-nine patients with advanced breast cancer were tested for the presence. in serum. of a
110 kDa soluble. c-erbB-2 fragment. Thirty-nine patients were seropositive. There was no correlation between
seropositivity and menopausal status. or with oestrogen status. In addition, no correlation could be found
between tissue c-erbB-2 immunostaining for the external domain of the c-erbB-2 receptor and the presence of
soluble c-erbB-2 in serum. The presence of serum soluble c-erbB-2 . however. had a significant impact on
survival of patients with advanced disease. suggesting that this test may become a useful independent
prognostic indicator.
Breast cancer is a major health problem. affecting one in nine
women in western countries. A particularly important goal is
the early identification of poor-risk patients who may benefit
from aggressive intervention with intensive chemotherapy.
While many tumour factors. including hormone receptor
status. ploidy and growth fraction. and the expression of
various oncogenes and proto-oncogenes by the tumour cells
have been proposed as prognostic indicators. the results, to
date. have been equivocal in a number of instances. Recent
investigations into the role of amplification of the c-erbB-2
gene. the product of which is a transmembrane protein with
extensive homology to the epidermal growth factor (EGF)
receptor. have also appeared to give somewhat contradictory
results. Gene amplification and increased c-erbB-2 expression
have been reported in approximately 20% of patients with
primary breast cancer (Clark & McGuire. 1991). Both gene
amplification and increased expression of the gene product
have been associated with a poorer prognosis in some
studies. The discriminant power may. however. be confined
to specific subsets of patients. Moreover. in a number of
studies the prognostic significance of c-erbB-2 expression
appears to be lost 5 or more years from diagnosis.
There has also been considerable interest, of late. in solu-
ble forms of cell-surface receptors. Circulating soluble recep-
tors include soluble forms of the insulin receptor and of the
interleukin 2 receptor. Serum levels of soluble interleukin 2
receptor (IL-2R) can be shown to correlate with disease
activity in autoimmune disorders (Rubin & Nelson. 1990)
and with tumour bulk in certain lymphomas. A soluble.
100 kDa. c-erbB-2 fragment has been detected in the serum
and effusions of patients with breast cancer (Mori et al..
1990: Leitzel et al.. 1992 and may provide prognostic inform-
ation in this disease.
We have undertaken a study of 79 patients with both
early- and advanced-stage breast cancer in an attempt to




Blood samples were obtained from 79 patients attending the
Breast Clinic of the Johannesburg Hospital between 1986 and
1993. Serum was stored at -20'C until assay. Sampling was
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performed at the time of diagnosis of recurrent or metastatic
disease. The 110 kDa, serum, soluble c-erbB-2 fragment was
measured using a serum c-erbB-2, enzyme-linked immuno-
assay kit (Triton Diagnostics. Alameda. CA. USA). Briefly.
monoclonal anti-c-erbB-2 antibody conjugates were added to
aliquots of serum, incubated for 2 h. followed by addition of
linking solution and then chromogen substrate. Absorbance
was read in a spectrophotometer at 450nm. Control and
calibrator samples were run with each assay. Controls
included samples from 24 healthy women falling into the
same age range as the patients with breast cancer. The
amount of c-erbB-2 protein was calculated from a standard
curve. Results are expressed as units per ml of serum. Serum
levels 10 uml-' were deemed positive. This level was
chosen as being two standard deviations above the mean for
healthy women and was also the upper limit for the negative
controls supplied with the kit. The antibody has no signi-
ficant cross-reactivity with epidermal growth factor (EGF).
and reacts only with the external domain of the c-erbB-2
molecule. Western blotting of samples with elevated levels
confirmed the presence of a 100 kDa protein in serum which
showed reactivity with this antibody.
Oestrogen receptor (ER) status and tissue c-erbB-2 were
also determined when suitable specimens were available. ER
was measured using the ERICA kit (Abbott Laboratories)
method according to the manufacturer's instructions. Tissue
c-erbB-2 determination was by means of immunohistochemis-
try using a monoclonal antibody to the external domain of
c-erbB-2 (Triton Diagnostics) and a standard avidin-biotin
procedure. Briefly. endogenous peroxidase was blocked using
methanolic peroxide, and then blocking antibody. pnrmary
and control antibodies, secondary antibody. ABC (Vecta-
stain) and diaminobenzidine (DAB) were layered on sequen-
tially. Specimens were deemed positive if clear membrane
immunostaining was observed. Suitable positive and negative
controls were incorporated into each assay procedure.
Statistical analvsis
Disease-free survival, overall survival and survival from
disease progression were analysed using SAS statistical soft-
ware. Additional variables analysed included age, sex. site of
disease, initial stage of disease, menopausal status and ER
status (where available). Survival curves were generated using
the method of Kaplan and Meier (1958). and were compared
using the log-rank statistic.
Ethical considerations
All patients gave informed consent prior to entry into the
study. The study was approved by the Committee on Ethics
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Forty-four out of 79 (56%) patients were post-menopausal at
time of diagnosis. The mean age at presentation was 51.4 +
13.1 (range 24-85) years. Further patient characteristics are
shown in Tables I and II.
Serum soluble c-erbB-2
Serum levels of the soluble fraction of c-erbB-2 ranged from
2 to 278 with a mean of 35 ± 57.6 u ml-'. Intra- and inter-
assay variation was <2%. Intra-patient variation of serum
c-erbB-2 levels, when levels were tested in blood samples
from 17 patients who had clinically stable disease and who
had two or more separate blood samples taken at intervals of
14 to <42 days, was also <2%.
Thirty-nine patients (49%) had serum soluble c-erbB-2
levels of > 10 u ml-'. There was no correlation between the
presence of elevated serum soluble c-erbB-2 level and men-
strual status (P = 0.66). There was, however, a significant
correlation between serum level and the type of treatment
chosen for patients with stage IV disease [27 of 42 (64%)
patients receiving chemotherapy were seropositive compared
with 11 of 32 (34%) receiving hormonal therapy] (Table II).
There was no correlation between the presence of raised
serum soluble c-erbB-2 level and any specific site of relapse.
Tissue c-erbB-2 immunostaining
Twenty-four patients had contemporaneous tumour tissue
and serum samples available for c-erbB-2 determination. Tis-
Table I Serum soluble c-erbB-2: patient characteristics and
seropositivity rate
Patient charac- Soluble c-erbB-2
teristics Positive Negative
Number (0%) Number (%0 Nwumber (%) P-value
Menopausal status
Pre 35 (44) 17 (49) 18 (51) NS
Post 44 (56) 22 (50) 22 (50)
Stage at presentation
I 4 (5) 1 (25) 3 (75)
11 31 (39) 1 1 (35) 20 (65)
III 19 (24) 10 (53) 9 (47)
IV 25 (32) 17 (68) 8 (32)
Stage at sampling
IV 74 (94) 39 (49) 40 (51)
ER status
Positive 15 (20) 7 (47) 8 (53)
Negative 25 (33) 12 (48) 13 (52) NS
Unknown 39 (47) 20 (51) 19 (49)
NS. not significant.
sue immunostaining did not correlate with the presence of
soluble c-erbB-2 in serum (Table III). The presence of posi-
tive tissue immunostaiing had no impact on overall survival.
time to relapse or on survival from progression (P= 0.26).
Oestrogen receptor lev els
There was no significant correlation between oestrogen recep-
tor expression among 37 patients of known receptor status
and serum soluble c-erbB-2 levels (P = 0.6).
Survival and time to relapse
The median overall survival of this cohort of patients from
time of initial diagnosis was 44 ± 7.4 months (range 1-254
months). Among the 74 patients who either presented with or
who had progressed to stage IV disease, the median survival
time from progression was 19 ± 24.7 months (range 1- 158).
The presence of soluble c-erbB-2 fragment in serum at the
time progression was diagnosed had a significant impact on
overall survival of these patients. Seropositive patients had a
median survival of 21 months vs 64 months for seronegative
patients (P = 0.03) (Figure 1). The prognostic impact of solu-
ble c-erbB-2 on survival was lost when the analysis was
confined to ER-positive patients. possibly because of the low
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Fgwe 1 Influence of the presence of soluble c-erbB-2 fragment
in the serum on prognosis of patients with breast cancer. Overall
survival. 0, Patients with serum soluble c-erbBO2 <10uml- ;
0, patients with serum soluble c-erbB-2 1OumlJ'.
Table m Breast tumour tissue expresson ofc-erbB-2 protein and the
presence of serum soluble c-erbB-2 fragment










Number (%) 0 Number (%J Number (%0) P-value
Treatment for stage IV disease
Hormonal 32 (42) 11 (34) 21 (66) p 05
Chemotherapy 42 (48) 27 (64) 15 (34)
Response to first-line therapy
Complete and partial
response 40 (52) 20 (50) 20 (50) NS
No response 34 (43) 18 (53) 16 (47)
NS. not significant.c-erbB-2 IN SERUM CORRELATES WITH BREAST CANCER STAGE 741
Response to therapy
Serum soluble c-erbB-2 had no influence on response to
either initial (P = 0.64) or salvage treatment for stage IV
disease (P = 0.78).
Discussion
The c-erbB-2 protein is a 185 kDa transmembrane protein
with tyrosine kinase activity. It comprises both an extracel-
lular and an intracellular domain. While the extracellular
domain has ligand-binding activity, the ligand has yet to be
clearly defined (Maguire & Green, 1989), but is thought to
act as a growth factor (Perez et al., 1993). Antibodies to
c-erbB-2 have been shown to inhibit both anchorage-depen-
dent and anchorage-independent growth in vivo (Xu et al.,
1993).
c-erbB-2 has been found to be amplified in 20-30% of
primary breast cancers, and gene amplification correlates
with oncoprotein overexpression. c-erbB-2's impact on prog-
nosis is. however, somewhat controversial. A number of
investigators have reported a correlation between c-erbB-2
amplification and survival in node-positive primary breast
cancer (Tandon et al., 1989; Borg et al., 1990). However,
both Zhou et al. (1989) and Toikkanen et al. (1992) failed to
demonstrate any impact of c-erbB-2 expression on survival in
node-positive patients. Conflicting results have also been
reported in node-negative patients (Wright et al., 1989; Pater-
son et al.. 1991). Allred et al. (1992) found a highly signi-
ficant correlation between disease-free survival and c-erbB-2
expression. but only in specific subsets of patients (small
tumour size, ER positive and no significant in situ compo-
nent), so-called 'low-risk patients'. Furthermore. while
Gusterson et al. (1992) found c-erbB-2 immunostaining to
have an overall prognostic impact only in patients with node-
positive disease. c-erbB-2-positive, node-negative patients
receiving adjuvant chemotherapy fared less well in their study
than those who were c-erbB-2 negative. These findings tended
to suggest that. whatever influence the presence of c-erbB-2
expression has on the biology of breast cancer. this effect is
confined to the earlier clinical phases of the illness.
In addition, it has been suggested that c-erbB-2 amplifica-
tion and protein expression correlate both with poor histo-
logical grade and lack of ER expression (Cline et al., 1987;
Schroeter et al., 1992). Poller et al. (1991) demonstrated that
overexpression of c-erbB-2 is significantly correlated with
S-phase and proliferative index in ductal carcinoma in situ
(P = 0.001), as well as in early invasive duct carcinoma
(P = 0.04).
There is also evidence to suggest that c-erbB-2 overexpres-
sion may be preferentially associated with certain histological
subtypes of breast cancer. Van de Vijver et al. (1988) des-
cribed a high incidence of c-erbB-2 overexpression in large-
cell, comedo-type ductal carcinoma in situ as compared with
invasive ductal carcinoma, suggesting either that the invasive
ductal carcinomas that are c-erbB-2 positive are derived from
a specific type (large-cell comedo) of ductal carcinoma in situ
or that c-erbB-2 expression may be lost during tumour inva-
sion and progression. Evidence supporting the first theory is
provided by Maguire et al. (1992), who found that while
tumours with c-erbB-2-negative in situ components had
immunonegative invasive components, tumours with immuno-
positive comedo-type in situ components had immunopositive
invasive ductal carcinoma. It should be pointed out. how-
ever. that the immunostaining was frequently more intense in
the in situ components than in the invasive carcinomas.
Soluble forms of the c-erbB-2 protein have been reported
in the serum of patients with breast cancer, and in addition
have been shown to correlate with disease bulk as well as
with tissue overexpression in an animal model (Langton et
al.. 1991). No reports have, however, been published to date
on the prognostic significance of soluble c-erbB-2 in patients
with breast cancer.
The present study examined a group of 79 women with
advanced breast cancer. The method used in this study mea-
sured a 100 kDa c-erbB-2 antigen fragment. which is not
detected in the serum of normal controls or in patients with
benign breast disease (Teramoto et al., 1991). A surprisingly
high frequency of elevated serum soluble c-erbB-2 levels was
found. possibly because this study included mainly patients
with aggressive disease. with 25 patients presenting with
advanced breast cancer and all but five of the remainder
having progressed to stage IV disease. In addition, there was
a statistically significantly higher incidence of seropositivity
in patients given chemotherapy as first-line therapy for pro-
gressive disease - indicative of the perception that these
patients were suffering from aggressive disease. In addition.
the presence of serum soluble c-erbB-2 fragment concentra-
tions of >10 u ml' had a significant impact on overall
survival from diagnosis of metastatic disease.
The lack of correlation between seropositivity and tissue
expression of c-erbB-2 raises some interesting possibilities.
While the lack of correlation may be due to low sample
number, definite tissue staining was demonstrated in 10 of
the 24 patients with tumour samples available for examina-
tion. This frequency was, again, a relatively high rate of
c-erbB-2 expression. While it may be argued that lack of
tissue immunostaiing is related to the sensitivity of the
method, both tissue-positive and serum-ngetaive as well as
tissue-negative and serum-positive cases were found. Among
the serum soluble c-erbB-2-negative patients with negative
tissue expression there were three patients with extremely
high serum levels (range 120-160 u ml') and with extensive
disease. while all four patients with negative serum soluble
c-erbB-2 tissue and positive tissue staining demonstrated
strong positive staining and also had extensive disease. Since
both the serum and tissue assays were performed using a
monoclonal antibody specific for the external domain of
c-erbB-2. these findings suggest the possibility that loss of
tissue expression may result from proteolytic cleavage, with
release of the external domain and transfer into the blood.
rendering the tissue negative to reaction with the antibody
used, or that the serum component represents an alterna-
tively spliced variant lacking the membrane domain. This
question will be addressed in future studies by using anti-
bodies to both the internal domain as well as to the external
domain of the c-erbB-2 molecule.
Whatever the pathophysiological explanation. assay for
soluble c-erbB-2 in serum is a relatively simple test. requiring
only a blood sample rather than tissue. Soluble c-erbB-2 may
offer prognostic information with seropositivity being a pre-
dictor of shorter survival in patients with breast cancer.
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